Early experience of seven hepatocellular carcinoma cases treated with regorafenib

Regorafenib became second‐line treatment for the patients with sorafenib refractory. In our study, two patients could not continue regorafenib for its adverse effects. It was suggested that appropriate use criteria of regorafenib should be observed and manage adverse effects earlier.

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Clin Case Rep
Main Authors: Uchikawa, Shinsuke, Kawaoka, Tomokazu, Aikata, Hiroshi, Kodama, Kenichiro, Inagaki, Yuki, Hatooka, Masahiro, Morio, Kei, Nakahara, Takashi, Murakami, Eisuke, Hiramatsu, Akira, Tsuge, Masataka, Imamura, Michio, Kawakami, Yoshiiku, Chayama, Kazuaki
פורמט: Artigo
שפה:Inglês
יצא לאור: John Wiley and Sons Inc. 2018
נושאים:
Case Reports
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6230610/
https://ncbi.nlm.nih.gov/pubmed/30455925
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.1791
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים